Sports

Eisai: Discovery Research on Twin Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Building 2024

Eisai: Discovery Research on Twin Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Building 2024

TOKYO, Mar 29, 2024 – (JCN Newswire) – Eisai Co., Ltd. announced this day that drug discovery research performed on lemborexant (mark title: Dayvigo), the dual orexin receptor antagonist found by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Building 2024 by the PSJ.

The PSJ Award for Drug Research and Building is one in every of a collection of awards presented by the PSJ and is devoted to researchers who win performed excellent research work that has contributed to medication thru the revolutionary building of a pharmaceutical drug or appropriate technology associated to the pharmaceutical sciences. Award recipients are evaluated by the PSJ in line with the ingenuity of the research itself as well to the effectiveness and security of the associated pharmaceutical product(s) or the innovativeness of the associated medical treatment or treatment technology. Eisai changed into as soon as a four-time winner of the award for drug discovery research: in 1998 on donepezil hydrochloride, an Alzheimer’s illness treatment; in 2013 on eribulin mesylate, an anti-cancer agent; in 2020 on lenvatinib, a multikinase inhibitor; and in 2021 on perampanel, an AMPA-kind glutamate receptor antagonist.

PSJ shared the next rationale for selecting lemborexant: “Unlike veteran medication, in line with the reality that the most most important reason of insomnia is the nocturnal hyperactivation of the wakefulness pathway, the compound targets inhibition of the wakefulness system, which is truly apt a rational therapeutic capability. The compound is extremely current in its outlandish building in line with trisubstituted cyclopropanes, and has overcome many challenges in its optimization to a compound with a balanced profile by overcoming many pharmacokinetic and security disorders. In preclinical and clinical reports, it has demonstrated a superior efficacy and security profile that sets it except for veteran medication, and the compound is assembly the unmet medical needs of many insomnia sufferers each and every in Japan and out of the nation.”

Lemborexant is currently licensed for the indication of insomnia in over 15 nations, including Japan, the U.S., Canada, Australia, and nations in Asia.

Eisai considers neurology, including insomnia, a therapeutic home of point of curiosity. Eisai strives to salvage revolutionary products in therapeutic areas with excessive unmet medical needs as soon as that it is most likely you’ll perchance perchance judge of, and must extra make a contribution to addressing the assorted needs of, as well to rising the advantages offered to, these living with the illness and their families.

Theme of awarded research:

Drug discovery research of lemborexant, original dual orexin 1/2 receptor antagonist for the treatment of sleep disorders

Award recipients:

– Taro Terauchi (Protein Integrity & Homeostasis Enviornment Head, DHBL, Eisai)
– Takashi Ueno (Senior Scientist, Global DMPK, BA Unit, Global PPD Characteristic, DHBL, Eisai)
– Shoji Asakura (Govt Director, Global Drug Safety, BA Unit, Global PPD Characteristic, DHBL, Eisai)
– Naoki Kubota (Director, Japan and Asia Scientific Building, CEG, DHBL, Eisai)
– Carsten Beuckmann (Feeble employee of Eisai)  

About Lemborexant (product title: DAYVIGO)

Lemborexant, an orexin receptor antagonist, is Eisai’s in-home found and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). In folks with recurring day-to-day sleep-wake rhythms, orexin signaling is believed to promote sessions of wakefulness. In folks with sleep-wake disorders, it is far that it is most likely you’ll perchance perchance judge of that orexin signaling which regulates wakefulness is no longer performing on the whole, suggesting that inhibiting execrable orexin signaling may well perchance enable initiation and maintenance of sleep. It has been licensed for the treatment of insomnia in over 15 nations including Japan, the US, Canada, Australia and nations in Asia.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Company Recordsdata Network.

Read Extra